Mednax continues its bullish rally to test new highs.
Regarding the fundamentals, we note the expected increase of sales by 45% by 2015. Moreover, the analysts forecast an average target price of USD 105, which represents a potential increase of 7% compared to the current price.
Technically, the share has a bullish configuration in the mid and long-term. Prices are supported by increasing moving averages as shown by the 20-period, in daily data, and enclose the stock in a dynamic upward trend.
Therefore, investors will benefit from the signal given by the breakout of the USD 98.7 resistance to take a long position in the stock. The objective will be set near USD 105. Once the position is opened, a stop loss should be fixed under effective entry point.
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. The Companyâs affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by more than 20 pediatric subspecialties, as well as pediatric primary and urgent care clinics. Its national network comprises over 2,620 affiliated physicians, including 1,330 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. It has over 580 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
PEDIATRIX MEDICAL GROUP, INC. 
